Simplify Logo
Amgen

Amgen

Biotech company creating biologic medicines

Associate Software Engineer

Full-TimeUpdated on 9/20/2026
$102.9k - $139.2k/yr

+ Annual bonus + Stock-based long-term incentives

Mid
Bachelor's, Master's, Associate's
Remote in USA
Remote

About the job

Requirements
  • A Master’s degree and 3 years of Information Systems experience, or a Bachelor’s degree and 4 years of Information Systems experience, or an Associate’s degree and 6 years of Information Systems experience, or a high school diploma/GED and 8 years of Information Systems experience.
  • Demonstrated experience developing, integrating, deploying, or supporting enterprise software or data solutions.
  • Proficiency in Python and SQL.
  • Experience working with cloud, data, automation, or enterprise application platforms.
  • Ability to independently deliver moderately complex technical assignments while collaborating within a cross-functional team.
  • Strong understanding of software architecture, modular development, design patterns, and maintainable application design.
  • Experience developing automation solutions using Python and one or more of PowerShell, Bash, Power Automate, Power Apps, or n8n.
  • Experience developing or integrating APIs, web services, microservices, event-driven solutions, or enterprise application interfaces.
  • Familiarity with CI/CD, DevOps practices, automated builds, automated deployment, application monitoring, logging, and operational support.
  • Working knowledge of source control and release-management practices using Git and GitLab.
  • Experience troubleshooting production issues and participating in incident response, root-cause analysis, and remediation.
  • Working knowledge of application security concepts, including secrets management, certificates, authentication, authorization, and access controls.
  • Experience working within Agile or Scrum delivery methodologies.
  • Ability to create technical documentation, including designs, diagrams, configuration instructions, and operational support procedures.
  • Ability to communicate effectively with technical and nontechnical stakeholders and collaborate across global, virtual, and cross-functional teams.
Responsibilities
  • Design, develop, configure, test, deploy, and support scalable enterprise software applications, platform capabilities, APIs, integrations, interfaces, reports, and automation solutions.
  • Own the technical implementation of assigned user stories and workstreams in collaboration with product managers, analysts, architects, engineers, and other technical team members.
  • Analyze business, functional, and technical requirements and translate them into technical designs, implementation tasks, data flows, integration patterns, and testable acceptance criteria.
  • Develop production-ready applications, services, and automation solutions using Python, SQL, and approved programming, scripting, workflow, and low-code technologies.
  • Design, develop, and support data pipelines, transformations, integrations, and data-quality controls using Python, SQL, PySpark, Databricks, and APIs.
  • Develop and maintain APIs, web services, microservices, event-driven solutions, and enterprise application integrations.
  • Build and deploy containerized solutions using Docker, Kubernetes platforms managed through Rafay, and AWS container services such as ECR, EKS, ECS, or Fargate.
  • Support DevOps and continuous-delivery practices, including source control, automated builds, CI/CD pipelines, release coordination, environment management, infrastructure automation, and deployment validation.
  • Develop and maintain unit, integration, regression, and automated tests.
  • Participate in peer reviews, code reviews, and technical design reviews.
  • Monitor application, integration, and data-pipeline health using logging, alerting, and observability tools.
  • Troubleshoot production incidents, software defects, integration failures, data issues, and performance problems; perform root-cause analysis and implement corrective actions.
  • Manage or support application secrets, certificates, authentication, authorization, identity integrations, and other application security controls.
  • Apply secure coding, access-control, data-protection, vulnerability-management, quality, and compliance requirements throughout the software lifecycle.
  • Develop prototypes and proofs of concept to evaluate technologies and validate technical approaches.
  • Create and maintain architecture diagrams, technical designs, API and integration specifications, configuration documentation, deployment procedures, operational runbooks, and support materials.
  • Identify technical risks, delivery constraints, security concerns, and cross-system dependencies, escalating issues when broader support is required.
  • Participate in Agile or Scrum ceremonies, including backlog refinement, sprint planning, estimation, demonstrations, retrospectives, and continuous-improvement activities.
  • Share technical knowledge and provide guidance to team members on assigned technologies, applications, and engineering practices.
  • Use approved AI-assisted development tools to improve engineering productivity, testing, documentation, and code quality.
  • Identify opportunities to incorporate AI-enabled capabilities into business applications, automation solutions, and internal developer tools while complying with security, privacy, and quality requirements.
Desired Qualifications
  • Experience delivering enterprise-grade software to production within a global, highly regulated, healthcare, pharmaceutical, or biotechnology environment.
  • Experience with Databricks, Apache Spark, PySpark, Delta Lake, or related data-engineering technologies.
  • Experience supporting applications or business stakeholders using Salesforce, Tableau, Power BI, Databricks, AWS, or GitLab integrations.
  • Experience building and deploying containerized applications using Docker, Kubernetes, Rafay, AWS ECR, AWS EKS, AWS ECS, or Fargate.
  • Experience with infrastructure automation, configuration management, or infrastructure-as-code technologies.
  • Experience integrating AI services, large language models, retrieval-augmented generation, or intelligent automation into business applications and internal developer tools.
  • Experience using AI-assisted development tools while maintaining controls for code quality, intellectual property, privacy, and cybersecurity.
  • Experience with application monitoring, observability, alerting, and performance-management technologies.
  • Familiarity with secure software-development practices, vulnerability remediation, identity integration, and cloud security controls.
  • Working understanding of business operations in Research and Development, Commercialization, Operations, Process Development, Commercial, or Marketing.
  • Experience working with geographically distributed development teams, vendors, business stakeholders, or managed-service providers.
  • Relevant certifications in cloud technologies, software development, data engineering, DevOps, cybersecurity, Agile, or enterprise platforms.

About the company

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen raised 2026 revenue guidance to $38.2 billion-$39.4 billion after Q2 outperformance.
  • Repatha sales jumped 37% to $953 million, driven by cardiologist and primary-care adoption.
  • MariTide now has nine ongoing and three planned Phase 3 studies across obesity.

What critics are saying

  • Prolia and XGEVA sales fell 33% in Q2 2026 as biosimilars hit.
  • FDA proposed withdrawing TAVNEOS in April 2026, threatening a marketed rare-disease franchise.
  • If MariTide misses 2027 endpoints, Amgen loses its next obesity growth pillar.

What makes Amgen unique

  • Amgen's six growth drivers produced nearly 70% of Q2 2026 product sales.
  • IMDELLTRA sales rose 115% in Q2 2026, validating Amgen's oncology engine.
  • Hyderabad's 2027 Science and Innovation Center expands Amgen's seven-lab global R&D network.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 11th, 2026
Revolution Medicines' first pancreatic cancer therapy approval challenges Amgen's biotech dominance

Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.

Yahoo Finance
Sep 11th, 2026
Amgen vs CRISPR Therapeutics: Which healthcare stock offers better value in 2026?

Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.

Yahoo Finance
Sep 11th, 2026
Amgen and AstraZeneca lung cancer drug combo meets survival goal in phase III study

Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.

Yahoo Finance
Sep 10th, 2026
Amgen vs. Moderna: Which healthcare stock is a better buy in 2026?

Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech serves 17 million patients globally with treatments for heart disease, obesity, and cancer. However, three distributors—McKesson, Cencora, and Cardinal Health—accounted for 77% of gross revenues, creating concentration risk. The company's debt-to-equity ratio stood at 6.3x. Moderna posted FY 2025 revenue of $1.9 billion, down 39.2% as pandemic-related vaccine demand declined. The mRNA specialist reported a net loss of $2.8 billion, resulting in a negative 145.2% net margin due to high research and development costs. The company is pivoting its mRNA platform toward infectious diseases, cancer, and rare conditions whilst expanding through partnerships like its collaboration with Merck.

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.